IL15 and neoplasm: In addition, we observed that almost all tumor cells lost expression of the target antigen on Day 8 after H9 CAR-IL15 T cell treatment, whereas most of tumor cells in the H9 CAR group, which exhibited comparable antitumor activity at this stage, maintained the expression of the target antigen; the underlying mechanism and significance of this observation remains unclear.